Citadel Advisors
INDV icon

Citadel Advisors’s Indivior Pharmaceuticals INDV Stock Holding History

Citadel Advisors’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.43M Buy
83,700
+26,300
+46% +$954K ﹤0.01% 5418
2026
Q1 		$1.75M Buy
57,400
+32,000
+126% +$1.06M ﹤0.01% 6375
2025
Q4 		$911K Buy
25,400
+8,800
+53% +$269K ﹤0.01% 7599
2025
Q3 		$400K Buy
16,600
+4,000
+32% +$83.7K ﹤0.01% 9671
2025
Q2 		$186K Buy
12,600
+6,900
+121% +$80.4K ﹤0.01% 10745
2025
Q1 		$54.3K Buy
5,700
+300
+6% +$3.15K ﹤0.01% 12233
2024
Q4 		$67.1K Buy
5,400
+3,800
+238% +$39.1K ﹤0.01% 12035
2024
Q3 		$15.6K Sell
1,600
-14,200
-90% -$166K ﹤0.01% 12961
2024
Q2 		$255K Buy
15,800
+15,700
+15,700% +$283K ﹤0.01% 9456
2024
Q1 		$2.14K Buy
+100
New +$1.88K ﹤0.01% 14039

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors's INDV Position: Q2 2026 in Review

Citadel Advisors reduced its Indivior Pharmaceuticals (INDV) stake by 25% in Q2 2026, selling an estimated $32.9M and leaving 2,667,827 shares worth $109M. The position accounts for 0.01% of the portfolio, ranked #911.

Citadel Advisors first reported a position in INDV in Q1 2024 and has held it in 10 quarters since. The position peaked at $110M in Q4 2025. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Citadel Advisors held 2,667,827 shares of Indivior Pharmaceuticals worth $109M as of Q2 2026.
  • Citadel Advisors sold 906,217 Indivior Pharmaceuticals shares in Q2 2026, an estimated $32.9M.
  • Indivior Pharmaceuticals made up 0.01% of Citadel Advisors's portfolio in Q2 2026, its #911 holding.
  • Citadel Advisors first reported a position in Indivior Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • Citadel Advisors's Indivior Pharmaceuticals position peaked at $110M in Q4 2025.
  • 338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.